Palisade Bio (NASDAQ:PALI – Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Palisade Bio to post earnings of ($2.39) per share for the quarter.
Palisade Bio Stock Down 15.0 %
Shares of NASDAQ PALI opened at $0.85 on Tuesday. Palisade Bio has a 52 week low of $0.75 and a 52 week high of $9.65. The firm’s fifty day moving average is $1.24 and its 200 day moving average is $2.27. The company has a market cap of $2.35 million, a price-to-earnings ratio of -0.06 and a beta of 1.49.
Analyst Ratings Changes
Separately, Brookline Capital Management began coverage on shares of Palisade Bio in a research note on Wednesday, November 20th. They issued a “buy” rating and a $38.00 target price on the stock.
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
Featured Articles
- Five stocks we like better than Palisade Bio
- What is the S&P 500 and How It is Distinct from Other Indexes
- Can TikTok Stock Picks Really Make You Rich?
- What Are Dividend Challengers?
- The “Quality” Rotation: Back to Basics Investing
- How to Calculate Stock Profit
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
